Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 8:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 398 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertrophic Clear all

Conditions: Hypertrophic Cardiomyopathy
Interventions: Echo and myocardial contrast echocardiography perfusion imaging; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 19 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Non-obstructive Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathy
Interventions: myPACE+ algorithm; Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety, Gastrointestinal Hemorrhage, Hepatomegaly, Lymphadenopathy, Macroglossia, Nausea, Primary Systemic Amyloidosis, Purpura, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
Interventions: Isatuximab, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 345
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • Burbank, California + 234 more

Conditions: Hypertrophic Skin Condition of Anterior Abdomen
Interventions: PICO 7 dressing, Standard wound dressing; Device · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Obstructive Sleep Apnea
Interventions: Tonsillectomy; Procedure
Lead sponsor: University of Southern California; Other
Eligibility: 17 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hepatomegaly, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Splenomegaly
Interventions: Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment; Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obstructive Sleep Apnea, Enlargement of Tonsil or Adenoid
Interventions: Caffeine and sodium Benzoate 10 mg/kg IV, Caffeine and Sodium Benzoate 20 mg/kg IV, 0.9 NS Saline; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 2 Years to 12 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bladder Cancer, Nerve Sheath Tumor, Nerve Sheath Tumors, Solid Tumor Malignancies, Solid Tumor Cancer, Solid Tumor Neoplasms, Advanced Solid Tumor, Bladder Neoplasm, Nerve Sheath Neoplasms, Nerve Sheath Tumor, Nos, Solid Tumor, Adult, Solid Carcinoma
Interventions: [89Zr]DFO-YS5, Positron Emission Tomography (PET)-Computerized tomography (CT); Drug · Procedure
Lead sponsor: Robert Flavell, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Familial Mediterranean Fever (FMF), Autoinflammation, Periodic Fever, Fever, Genetic Diseases, ROSAH, ALPK1
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 2 Months to 115 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1994
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 1 more

Conditions: Benign Prostatic Hypertrophy
Interventions: Richard Wolf 24F Laser scope, Karl Storz 28F Laser Scope; Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years · Male only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction, Left Atrial Dilatation, Left Ventricular Diastolic Dysfunction, Kidney Diseases, Kidney Injury, Kidney Dysfunction, Sodium Urine High, Blood Pressure Disorders, Uric Acid Retention, Angiotensin Hypertension, Autonomic Dysfunction, Autonomic Imbalance, Pediatric Kidney Disease, Pediatric Obesity, Proteinuria, Albuminuria
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 7 Years to 18 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post ET MF, Post PV MF
Interventions: AVID200; Drug
Lead sponsor: John Mascarenhas; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Keloid
Interventions: Not listed
Lead sponsor: Tirgan, Michael H., M.D.; Individual
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertrophic Cardiomyopathy
Interventions: on-pump intracardiac echocardiography; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: BPH, Prostate Hyperplasia, Urinary Frequency/Urgency
Interventions: MRI Guided Transrectal Periuretheral Transitional Zone Ablation; Device
Lead sponsor: Prostate Laser Center, PLLC; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sarcopenia, Cardiovascular Disease
Interventions: Resistance Training, Sedentary; Behavioral
Lead sponsor: Texas A&M University; Other
Eligibility: 50 Years to 69 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2018
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Hypertrophic Cardiomyopathy
Interventions: losartan, placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sleep Apnea, Obstructive, Hypoxia, Hypercapnia, Sleep Disorders, Obesity, Hypertension, Coronary Artery Vasospasm, Right Ventricular Overload, Left Ventricular Function Systolic Dysfunction, Ventricular Hypertrophy
Interventions: Clinically prescribed CPAP therapy; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 50 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hypertrophic Cardiomyopathy (HCM), Cardiomyopathy, Genetic Disease, Cardiology
Interventions: Large Language Model; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Nonobstructive Hypertrophic Cardiomyopathy
Interventions: HTX-001; Drug
Lead sponsor: Haya Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • Kansas City, Missouri • Cincinnati, Ohio

Conditions: Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure, Cardiomyopathies
Interventions: MYDICAR Phase 1, MYDICAR Phase 2, Placebo Phase 2 only; Genetic
Lead sponsor: Celladon Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 4
States / cities: La Jolla, California • San Diego, California • Kansas City, Missouri + 1 more

Conditions: Fibrosis, Scarring, Scar, Wounds, Injuries, Keloid, Cicatrix, Hypertrophic
Interventions: LED-RL Phototherapy, Mock Therapy; Device
Lead sponsor: Jared Jagdeo, MD, MS; Federal
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Mather, California

Conditions: Metastases
Interventions: Yttrium-90 (Y-90) resin microspheres; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myocardial Infarction, Heart Failure, Heart Enlargement
Interventions: PG-116800 (given as PG-530742), Placebo tablet; Drug
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 21
States / cities: Little Rock, Arkansas • Merced, California • Denver, Colorado + 18 more

Search by objective public record fields.

Perfusion Imaging With Myocardial Contrast Echocardiography in HCM

Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Negative Pressure Wound Therapy-PICO: Cosmesis in Repeat C-Sections

Tonsillectomy in Adults With Tonsillar Hypertrophy and Obstructive Sleep Apnea

Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis

Caffeine in Children With Obstructive Sleep Apnea, Dose Response Study

Imaging Study of [89Zr]DFO-YS5 for Cancer Detection

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

Wolf 24 F vs. Storz 28 F Laser Sheath Size for HoLEP

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

MPN-RC 118 AVID200 in Myelofibrosis

Keloid Radiation Registry

OPIE in the Thin Interventricular Septum

MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH)

Egg Cholesterol Consumption, Blood Cholesterol and Skeletal Muscle Hypertrophy

Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy

"Reversibility of Cardiovascular Injury With CPAP Use: Mechanisms Involved"

Large Language Models To Improve the Quality of Care of Cardiology Patients

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001

A Phase 1/2 Study of High-dose Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

High Fluence Light Emitting Diode-Red Light (LED-RL) in Human Skin

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

Study of Oral PG-116800 Following a Heart Attack